Prescription drug spending is rising, and the pharmaceutical industry's main lobbying organization is running a campaign to change how reporters describe it. Lobbying, at its most basic, means paid outreach designed to move policy or public opinion in a client's favor. PhRMA, the industry's primary trade and lobbying shop, has been circulating news releases and talking points to journalists with the goal of redirecting attention away from what STAT News calls a clear-cut increase in spending.
What news releases and talking points are meant to do
A news release is a pre-packaged document written to resemble a news story, framed entirely from the sender's vantage point. Talking points are shorter: compressed arguments designed to be repeated across interviews and briefings.
Neither format is secret, and neither is unusual. Lobbying groups send these materials to reporters routinely. The strategy, when it works, is to set the terms of a story before the reporter does. If the first document a journalist reads on a topic frames drug costs as something other than a problem, that frame can quietly shape the questions they ask, even when they intend to report independently.
What PhRMA wants journalists to overlook
The specific target of this campaign, as reported by STAT, is the rise in prescription drug spending itself. STAT characterizes that rise as clear-cut, a word that signals the data is not ambiguous or contested at the level of measurement. PhRMA has not, based on available reporting, disputed that spending has increased. The effort appears aimed at how reporters interpret the increase, not whether it happened.
That separation between a fact and its framing is where lobbying campaigns do most of their work. Spending went up is a measurement. Why it went up, and whether that should concern anyone, is an argument. PhRMA's outreach targets the argument.
Bob Herman, a health care reporter at STAT News, flagged the campaign in the outlet's Health Care Inc. newsletter.